肿瘤细胞治疗研究
英文原题：Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.
我们分析了向EBMT报告的1,191例患者（年龄70岁）（tisa-cel n=402；axi-cel n=789）。
嵌合抗原受体(CAR)T细胞疗法对复发/难治性大B细胞淋巴瘤(LBCL)有效，但在老年患者(70岁)中的证据有限。我们比较了tisagenlecleucel(tisa-cel)和axicabtagene ciloleucel(axi-cel)的结局，并评估了预后因素。我们分析了报告至EBMT的1,191例患者(年龄70岁)(tisa-cel n=402；axi-cel n=789)。中位随访时间为22.7个月。结局包括细胞因子释放综合征(CRS)、免疫效应细胞相关神经毒性综合征(ICANS)、总生存期(OS)、无进展生存期(PFS)、复发率(RI)和非复发死亡率(NRM)。多变量模型对年龄、性别、ECOG、疾病状态、既往移植和输注年份进行了校正。输注时的中位年龄为74岁；65.6%的患者年龄为70-75岁。tisa-cel和axi-cel输注时疾病进展的比例分别为59%和53%(p=0.04)。Tisa-cel患者年龄更大(74.0 vs 73.7岁，p=0.019)。在第30天，CRS(任何级别)发生率分别为62%和77%(p。
Chimeric antigen receptor(CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma(LBCL), but evidence in elderly patients( 70y) is limited. We compared outcomes of tisagenlecleucel(tisa-cel) and axicabtagene ciloleucel(axi-cel) and assessed prognostic factors. We analyzed 1,191 patients(aged 70y) reported to the EBMT(tisa-cel n=402; axi-cel n=789). Median follow-up was 22.7 months. Outcomes included cytokine release syndrome(CRS), immune effector cell-associated neurotoxicity syndrome(ICANS), overall survival(OS), progression-free survival(PFS), relapse incidence(RI), and non-relapse mortality(NRM). Multivariable models adjusted for age, sex, ECOG, disease status, prior transplantation, and year of infusion. Median age at infusion was 74y; 65.6% were aged 70-75y. Progressive disease at infusion was 59% vs 53% for tisa-cel and axi-cel(p=0.04). Tisa-cel patients were older(74.0 vs 73.7y, p=0.019). At day-30, CRS(any grade) occurred in 62% vs 77%(p.
MEMBER ACCOUNT
登录成功会直接打开下一页。
